Loading...
OTCM
CSLLY
Market cap77bUSD
Jul 10, Last price  
80.73USD
1D
0.72%
1Q
8.22%
Jan 2017
122.58%
Name

CSL Ltd

Chart & Performance

D1W1MN
P/E
14.80
P/S
2.66
EPS
5.46
Div Yield, %
1.64%
Shrs. gr., 5y
1.34%
Rev. gr., 5y
4.30%
Revenues
14.69b
-24.99%
2,096,817,3362,114,029,1772,690,752,3323,402,820,4853,730,499,2413,786,870,3524,475,508,1974,536,913,8504,950,400,0005,334,800,0005,458,600,0008,120,856,5739,166,717,72110,131,642,14811,899,410,47913,575,278,03213,761,477,64114,469,426,37119,585,285,15714,690,000,000
Net income
2.64b
-20.81%
416,718,51687,084,638457,420,695671,445,929924,824,870894,829,3881,005,280,7641,005,587,7351,216,300,0001,307,000,0001,379,000,0001,707,310,6361,337,400,0001,728,900,0002,682,922,1123,136,313,6163,183,882,5363,109,111,2863,336,069,5222,642,000,000
CFO
2.81b
-27.27%
567,822,000522,164,000480,840,000715,336,0001,024,824,0001,168,492,0001,018,119,0001,160,000,0001,414,231,8051,444,479,8301,775,520,8331,619,636,4421,652,982,0642,454,829,8852,299,367,8643,711,814,1124,855,454,3823,624,837,3793,866,807,8552,812,389,232
Dividend
Sep 10, 20240.725 USD/sh
Earnings
Aug 11, 2025

Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
URL
https://www.csl.com/
IPO date
Jun 08, 1994
Employees
32,065
Domiciled in
AU
Incorporated in
AU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
14,690,000
-24.99%
19,585,285
35.36%
Cost of revenue
10,988,000
14,495,736
Unusual Expense (Income)
NOPBT
3,702,000
5,089,549
NOPBT Margin
25.20%
25.99%
Operating Taxes
661,000
622,911
Tax Rate
17.86%
12.24%
NOPAT
3,041,000
4,466,638
Net income
2,642,000
-20.81%
3,336,070
7.30%
Dividends
(1,266,000)
(1,613,028)
Dividend yield
0.88%
1.20%
Proceeds from repurchase of equity
40,000
34,000
BB yield
-0.03%
-0.03%
Debt
Debt current
944,000
1,055,000
Long-term debt
12,903,000
13,587,684
Deferred revenue
2,415,684
Other long-term liabilities
918,000
8,095,616
Net debt
12,027,000
11,913,021
Cash flow
Cash from operating activities
2,812,389
3,866,808
CAPEX
(566,079)
(2,515,432)
Cash from investing activities
(1,259,000)
(17,606,538)
Cash from financing activities
(1,284,000)
677,918
FCF
7,237,918
2,372,671
Balance
Cash
1,657,000
2,325,546
Long term investments
163,000
404,116
Excess cash
1,085,500
1,750,398
Stockholders' equity
19,766,854
27,296,839
Invested Capital
31,354,444
44,172,024
ROIC
8.05%
13.67%
ROCE
10.88%
10.58%
EV
Common stock shares outstanding
485,199
483,886
Price
295.21
6.43%
277.38
3.09%
Market cap
143,235,687
6.72%
134,220,424
6.11%
EV
157,297,361
149,198,118
EBITDA
3,702,000
6,324,965
EV/EBITDA
42.49
23.59
Interest
420,000
750,764
Interest/NOPBT
11.35%
14.75%